 |
|
ORNL advances therapy for Parkinson's, other diseases
July 23, 2009By miniaturizing a device that monitors the delivery of healthy cells, researchers at Department of Energy's Oak Ridge National Laboratory are developing a powerful instrument for physicians to use in treating patients with Parkinson's syndrome, brain tumors and other diseases.
While cell replacement therapies can be effective, the challenge is to deliver a sufficient quantity of healthy cells, said Boyd Evans III of the lab's Measurement Science and Systems Engineering Division.
"Regardless of the source of cells and the location of delivery, there is a great need to improve cell viability after the cells are transplanted," Evans said. "The vast majority of transplanted cells do not survive more than 24 hours regardless of their source."
Studies have shown that merely implanting more cells does not necessarily increase the number that survive and differentiate into dopamine-producing, or viable, cells in Parkinson's models. The key is being able to deliver precise quantities of healthy cells to a targeted location. This requires the ability to determine if the cells are viable upon delivery and the ability to make meaningful measurements. ORNL's proprietary instrumented cell delivery catheter allows physicians to do just that.
"Our approach consists of monitoring cells that are implanted using a catheter equipped with a fiber optic probe to perform fluorescence-based cytometric measurements on cells as they exit the port at the catheter tip," Evans said. These measurements confirm that the cell is alive and provide indications of the cell's health.
"What we have done is taken the function of a laboratory instrument and put it on the tip of a catheter that can make measurements inside the brain," Evans said.
Results from several studies underscore the value of delivering a highly controlled amount of tissue into the host brain, and understanding cell viability at the delivery point is critical for meaningful comparison of experimental results, according to Evans.
The instrumented catheter is part of a larger effort to develop a complete system for collecting healthy tissue from an individual who is both the donor and recipient, expanding this tissue in vitro and implanting the tissue under monitored conditions. Joining Boyd in this effort are other researchers from ORNL, George Gillies of the University of Virginia, and neurosurgeon William Broaddus and neuroscientist Helen Fillmore of Virginia Commonwealth University.
Funding provided through ORNL's Laboratory Directed Research and Development program was used to develop a prototype device and demonstrate its functionality for characterizing cell flows of cell.
Following completion of the LDRD funded project, NexGen Medical Systems and Kopf Family Foundation at the University of Virginia, and the Cullather, Hord and Hafner Funds at Virginia Commonwealth University worked on other issues associated with flows of slurries of cells, such as cell delivery, cell selection and culturing technique.
DOE/Oak Ridge National Laboratory
Studies have shown that merely implanting more cells does not necessarily increase the number that survive and differentiate into dopamine-producing, or viable, cells in Parkinson's models. The key is being able to deliver precise quantities of healthy cells to a targeted location. This requires the ability to determine if the cells are viable upon delivery and the ability to make meaningful measurements. ORNL's proprietary instrumented cell delivery catheter allows physicians to do just that.
"Our approach consists of monitoring cells that are implanted using a catheter equipped with a fiber optic probe to perform fluorescence-based cytometric measurements on cells as they exit the port at the catheter tip," Evans said. These measurements confirm that the cell is alive and provide indications of the cell's health.
"What we have done is taken the function of a laboratory instrument and put it on the tip of a catheter that can make measurements inside the brain," Evans said.
Results from several studies underscore the value of delivering a highly controlled amount of tissue into the host brain, and understanding cell viability at the delivery point is critical for meaningful comparison of experimental results, according to Evans.
The instrumented catheter is part of a larger effort to develop a complete system for collecting healthy tissue from an individual who is both the donor and recipient, expanding this tissue in vitro and implanting the tissue under monitored conditions. Joining Boyd in this effort are other researchers from ORNL, George Gillies of the University of Virginia, and neurosurgeon William Broaddus and neuroscientist Helen Fillmore of Virginia Commonwealth University.
Funding provided through ORNL's Laboratory Directed Research and Development program was used to develop a prototype device and demonstrate its functionality for characterizing cell flows of cell.
Following completion of the LDRD funded project, NexGen Medical Systems and Kopf Family Foundation at the University of Virginia, and the Cullather, Hord and Hafner Funds at Virginia Commonwealth University worked on other issues associated with flows of slurries of cells, such as cell delivery, cell selection and culturing technique.
DOE/Oak Ridge National Laboratory
Brain Tumors Current Events and Brain Tumors News RSSResearchers Identify Role of Gene in Tumor Development, Growth and Progression
Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis.
Barrow study identifies new way to biopsy brain tumors in real time
A new miniature, hand-held microscope may allow more precise removal of brain tumors and an easier recognition of tumor locations during surgery.
Brain tumors in childhood leave a lasting mark on cognition, life status
Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.
The Largest Congress Worldwide on Ion Therapy in Heidelberg
The largest congress worldwide on the topic of particle or ion therapy - radiation with heavy ions and protons - has taken place in the fall of 2009 in Heidelberg.
Exercise can aid recovery after brain radiation
Exercise is a key factor in improving both memory and mood after whole-brain radiation treatments in rodents, according to data presented by Duke University scientists at the Society for Neuroscience meeting.
Researchers report benefits of new standard treatment study for rare pediatric brain cancer
A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor.
Unequal access: Hispanic children rarely get top-notch care for brain tumors
Hispanic children diagnosed with brain tumors get high-quality treatment at hospitals that specialize in neurosurgery far less often than other children with the same condition, potentially compromising their immediate prognosis and long-term survival, according to research from Johns Hopkins published in October's Pediatrics.
Survivors of childhood cancer less likely to marry
Childhood cancer survivors typically suffer from the long-term effects of cancer treatment on physical health, and results of a new study suggest that social implications also exist, which may affect their chance of an "I do" at the altar.
Stereotactic radiosurgery preferred method of treating cancer patients with brain metastases
Cancer patients who receive stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) for the treatment of metastatic brain tumors have more than twice the risk of developing learning and memory problems than those treated with SRS alone, according to researchers at The University of Texas M. D. Anderson Cancer Center.
New Approach for the Treatment of Malignant Brain Tumors
Initial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence.
More Brain Tumors Current Events and Brain Tumors News Articles
 |
Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black (Author) Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors. This invaluable resource tells patients everything they need to know to understand and address their diagnosis, in a four-part structure: • “What is a Brain Tumor?" provides straightforward information about how brain tumors are diagnosed, the different types of tumors and how they develop, and where to go for treatment. • “Coping with Shock” addresses the emotional... |
 |
Curveball: When Life Throws You a Brain Tumor by Liz Holzemer (Author) Life seemed idyllic for thirty-two-year-old Liz Holzemer. Wife of Major League Baseball pitcher Mark Holzemer, Liz was enjoying a successful career as a journalist when an MRI revealed a baseball-size brain tumor she soon found out was called meningioma. Told with clarity and unwavering humor, this book is an inspirational and informative account of one woman’s battle for her life. It shows how she emerged from this frightening diagnosis and two brain surgeries retaining her remarkable spirit of survival and renewed sense of purpose and hope. With practical information about meningioma and brain surgery, Curveball is a manual for people who face life-altering challenges and is also proof that one need not fight such battles alone. |
 |
Guerilla Guide to Brain Tumors: Shameless Dirty Tricks to beat the system and STAY ALIVE! by Skip Goebel (Author) In an unprecedented format, the Guerilla Guide to Brain Tumors is written in a format that combines the layout of the For Dummies series with a drill-sargent's attitude. (the back page says it all) This is a book of War Nothing warm and fuzzy or socially acceptable here and nothing about "Dying with Dignity". Just what it takes to win. And win you will, complete with a trail of wreckage behind you. It's a book for the patient, NOT the caregiver. The Guerilla Guide to Brain Tumors is a book that will take you out of the "Grovel and Wretch" mode and into the "Command and Dominate" mode with the following factions of our society: The Medical EstablishmentThe Social Services EstablishmentChurch, Friends and FamilyAnd most importantly...Yourself No punches are pulled here. Prepare to be... |
 |
Brain Tumors: Leaving the Garden of Eden--A Survival Guide to Diagnosis, Learning the Basics, Getting Organized, and Finding Your Medical Team by Paul M. Zeltzer (Author) A guidebook for the 150,000+ people/ year and families affected by brain tumors. This book will help you learn the basics about diagnosis, getting organized and finding your medical team. Included are chapters on all major types of brain tumors & metastases, glossary, medications, using the Internet to search for information, and getting a second opinion. "Brain Tumors:Leaving the Garden of Eden" is all about improving your odds by gathering information, & assessing your situation: What you need to do; what you need to know; what you can do now! |
 |
Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by Harry Wolf (Author) June 3, 2002 was the day that changed my life forever. A 43-year-old father of three, whom in oneday went from being a successful senior manager to a man with a braintumor. I have a glioblastoma multiformegrade IV brain tumor, the most deadly and aggressive type of brain tumor. This book covers how I have dealt with lifeafter being informed that I have a tumor that only 1-2% survive for 2years. I share the experiences, thoughts,and events from my first year as a survivor. When I was first diagnosed, I searched for a book that covered thedetails of what could be expected on both a medical and personal level. I could not find, so I wrote one. I maintained a detailed journal. I cover the first surgery, an awakecraniotomy, and the subsequent head infection that led to a second... |
 |
Brain Tumors: An Encyclopedic Approach by Andrew H. Kaye MD MBBS FRACS (Editor), Edward R. Laws MD FACS (Editor) (Churchill Livingstone) Second author, Edward R. Laws, Jr. Extensive reference providing a systematic updating of the chapters from the previous edition, c1995, with a number of new contributors. Retains an encyclopedic approach and includes key points and key references where appropriate. Color and halftone illustrations. For neurosurgeons. |
 |
Tumors of the Brain and Spine (M.D. Anderson Cancer Care Series) by Franco DeMonte (Editor), Mark R. Gilbert (Editor), Anita Mahajan (Editor), Ian E. McCutcheon (Editor), R. Sawaya (Editor), W.K.A. Yung (Editor) Tumors of the Brain and Spine focuses primarily on the standard approaches to the treatment of benign, primary low-grade to high-grade, and metastatic tumors in the brain and spine used by surgeons and clinicians at The University of Texas M. D. Anderson Cancer Center. It is written mainly for the primary care oncologist, general neurologist, and general neurosurgeon. Chapters on treatment focus on neurosurgery, chemotherapy, and radiation therapy, both singly and in combination. Chapters on symptom management, the molecular genetics and neuropathology of intracranial tumors, the leptomeningeal dissemination of systemic cancer, the epidemiology of brain tumors, and innovative treatment strategies round out the volume. |
 |
100 Q&A About Brain Tumors (100 Questions & Answers) by Virginia Stark-Vance (Author) Consumer text provides authoritative, practical answers to questions regarding treatment options, post-treatment quality of life, and sources of support. Co-authored by a brain-tumor survivor, text explains what to expect after the diagnosis and the treatment of a brain tumor. Softcover. |
 |
Brain Tumors: Practical Guide to Diagnosis and Treatment (Neurological Disease and Therapy) by Joachim M. Baehring (Editor), Joseph M. Piepmeier (Editor) Emphasizing new and emerging therapies in each chapter, this reference provides essential information for clinicians to provide accurate diagnoses and select the most appropriate treatment regimens for patients with primary and metastatic brain tumors and neurological complications of cancer. Edited by a leading cast of authorities on the topic-including the Chief and Associate Editors of the Journal of Neuro-oncology-this easily-accessible guide reviews the epidemiology, identification, and management of brain tumors while exploring the latest advances in this increasingly diverse field. |
 |
Brain Surgeon: A Doctor's Inspiring Encounters with Mortality and Miracles by Keith Black (Author), Arnold Mann (Author) Welcome to tiger country: the treacherous territory where a single wrong move by a brain surgeon can devastate-or end-a patient's life. This is the terrain world-renowned neurosurgeon Keith Black, MD, enters every day to produce virtual medical miracles. Now, in BRAIN SURGEON, Dr. Black invites readers to shadow his breathtaking journeys into the brain as he battles some of the deadliest and most feared tumors known to medical science. Along the way, he shares his unique insights about the inner workings of the brain, his unwavering optimism for the future of medicine, and the extraordinary stories of his patients-from ministers and rock stars to wealthy entrepreneurs and uninsured students-whom he celebrates as the real heroes. BRAIN SURGEON offers a window into one man's... |
| © 2009 BrightSurf.com |